Read news on drug conjugate with our app.
Read more in the app
Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated lung cancer
Phase 1 Study Supports Recommended Phase 3 Dose for Investigational EGFR x HER3 Antibody-Drug Conjugate in EGFR-Mutated Lung Cancer
New antibody-drug conjugate shows clinical benefit for advanced platinum-resistant ovarian cancer - EurekAlert!
New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients - EurekAlert!
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer - EurekAlert!
ASCO: HER3-targeted antibody-drug conjugate (ADC) shows promise for treatment-resistant solid tumors - EurekAlert!
Antibody-drug conjugate found effective against brain metastases in patients with HER2-positive breast cancer
Antibody-drug conjugate found effective against brain metastases in patients with HER2-positive breast cancer - EurekAlert
